# Study of FID-022 in Participants With Advanced Solid Tumors

Source: https://onco.cc/trials/nct06694480/  
OnCo record `nct06694480` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 1 trial of FID-022 run by Fulgent Pharma LLC., now recruiting.

## Summary

Study of FID-022 in Participants With Advanced Solid Tumors is a phase 1 interventional study registered as NCT06694480 by Fulgent Pharma LLC., with 24 participants planned, started 2025-07-03. Conditions recorded: Advanced Solid Tumors. Interventions recorded: FID-022.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-11-03
- Tags: pipeline; ctgov-ingest
- Registry id: NCT06694480
- Phase: 1
- Setting: A First-in-Human Phase 1 Dose Escalation Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of FID-022 as Monotherapy in Patients With Advanced Solid Tumors
- Sponsor: Fulgent Pharma LLC.
- Enrolled: 24

## Sources

- ClinicalTrials.gov NCT06694480: https://clinicaltrials.gov/study/NCT06694480

## Connected records

- cancers: [Metastatic cancer (cancer that has spread)](https://onco.cc/cancers/metastatic-cancer/)
- drugs: [FID-022](https://onco.cc/drugs/fid-022/)
- companies: [Fulgent Genetics](https://onco.cc/companies/fulgent-genetics/)

---
JSON: https://onco.cc/api/v1/entities/nct06694480.json